Silverback’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Silverback is a biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of cancer and fibrosis. Read more

Silverback is a biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of cancer and fibrosis. Read more

Laura Shawver's photo - President & CEO of Silverback

President & CEO

Laura Shawver

CEO Approval Rating

90/100

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

FibroGen is seen as one of Silverback's biggest rivals. FibroGen was founded in 1993 in San Francisco, California. FibroGen operates in the Biotechnology industry. FibroGen generates $290M more revenue than Silverback.

NexImmune is one of Silverback's top competitors. NexImmune was founded in 2011, and its headquarters is in Gaithersburg, Maryland. NexImmune operates in the Biotechnology industry. NexImmune has 110 more employees than Silverback.

bluebird bio is one of Silverback's top rivals. bluebird bio was founded in 1992, and is headquartered in Cambridge, Massachusetts. bluebird bio is in the Biotechnology field. bluebird bio generates $237.7M more revenue vs. Silverback.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $2M a good estimate for Silverback's revenue?

Acquisitions

No recent acquisitions found related to Silverback

Silverback Funding History

$10M$10M$57.5M$221M

Since Silverback was founded in 2016, it has participated in 6 rounds of funding. In total Silverback has raised $221.0M. Silverback's last funding round was on Sep 2020 for a total of $85.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series C
Sep 2020
$85M

EcoR1 Capital

Series B
Mar 2020
$78.5M
Series A
Sep 2018
$47.5M
Equity
Dec 2017
$3.7K
-
Equity
Mar 2016
$10M
-

Total Funding: $221M

Since Silverback was founded in 2016, it has participated in 6 rounds of funding. In total Silverback has raised $221.0M. Silverback's last funding round was on Sep 2020 for a total of $85.0M

Investments

No recent investments found related to Silverback

Silverback News

September 23, 2020Zephyr Net

Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1

After banking $78.5 million six months ago, Silverback Therapeutics is back for more. The immuno-onco... See more »
June 4, 2020Talent4Boards

Silverback Therapeutics appoints Vickie Capps to its Board of Directors

Talent4Boards - Great Talent builds Great Boards- USA, WA - Silverback Therapeutics, a biopharmaceuti... See more »
May 15, 2020MarketScreener

to Present Preclinical Data from Lead ImmunoTAC Candidate, SBT6050, at Upcoming ASCO Virtual Scientific Program and AACR Virtual Annual Meeting

(marketscreener.com) Data highlights systemically delivered, tissue-directed, localized activation of... See more »
April 29, 2020The Business Journals: Seattle

Silverback Therapeutics' new CEO aims to expand its oncology portfolio

Laura Shawver is telecommuting from San Diego due to the coronavirus pandemic. She expects to move up... See more »
April 22, 2020Talent4Boards

Silverback Therapeutics appoints Dr Laura Shawver to its Board of Directors as CEO

Talent4Boards - Great Talent builds Great Boards- USA, WA - Silverback Therapeutics today announced t... See more »
March 11, 2020BioSpace

Silverback Therapeutics Raises $78.5 Million to Advance Cancer Antibody Conju...

The financing round brings the company's total investments up to about $125 million.... See more »
March 11, 2020Xconomy

Silverback Therapeutics Adds $79M to Test HER2+ Tumor-Targeting Drug

In the four years that Silverback Therapeutics has been developing cancer immunotherapies that avoid ... See more »

Silverback Press Releases

February 28, 2019PR Newswire

Silverback Therapeutics to Present Data for Lead Therapeutic Candidate SBT6050 at American Association of Cancer Research Annual Conference

SEATTLE, Feb. 27, 2019 /PRNewswire/ -- Silverback Therapeutics, Inc., a biotechnology company develop... See more »

Headquarters

500 Fairview Avenue N Suite 600

Seattle, Washington98109

1-206-456-2900

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Silverback is a biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of cancer and fibrosis. Silverback was founded in 2016. Silverback's headquarters is located in Seattle, Washington, USA 98109. It has rais...

CEO

Silverback's President & CEO, Laura Shawver, currently has an approval rating of 90%. Silverback's primary competitors are FibroGen, NexImmune & bluebird bio.

Website

silverbacktx.com

Frequently Asked Questions about Silverback

  1. When was Silverback founded?

    Silverback was founded in 2016
  2. Who is Silverback's CEO?

    Silverback's CEO is Laura Shawver
  3. How much revenue does Silverback generate?

    Silverback generates $2M in revenue
  4. How much funding does Silverback have?

    Silverback has historically raised $221M in funding
  1. Where is Silverback's headquarters?

    Silverback's headquarters is in Seattle Washington, USA
  2. How many employees does Silverback have?

    Silverback has 40 employees
  3. What sector does Silverback operate in?

    Silverback is in Health Care Services, Health Care Technology
  4. Who are Silverback's competitors?

    Silverback's top competitors are FibroGen, NexImmune, bluebird bio